Related Experiment Videos
Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice
1Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario, Canada. aaron.schimmer@utoronto.ca
Cancer Research
|October 20, 2004
Summary
Inhibitor of Apoptosis Proteins (IAPs) are key regulators of cell death and survival. Research is exploring their role in cancer diagnosis and treatment, with challenges in clinical application.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Inhibitor of Apoptosis Proteins (IAPs) are a protein family that inhibit caspases, crucial for apoptosis.
- Beyond apoptosis, IAPs regulate cell division, cell cycle, and signal transduction pathways.
- IAP dysregulation is implicated in various malignancies.
Purpose of the Study:
- To review the multifaceted roles of IAPs in cellular processes.
- To highlight the translation of IAP research into clinical applications for malignancy.
- To discuss the potential of IAPs as diagnostic markers and therapeutic targets.
Main Methods:
- Literature review of IAP functions and clinical relevance.
- Analysis of IAP roles in cell death, cell cycle, and signaling.
- Examination of IAPs as biomarkers and therapeutic targets in cancer.
Main Results:
- IAPs inhibit caspases 3, 7, and 9, but not caspase 8.
- IAPs, like survivin, are investigated as diagnostic markers for occult malignancy.
- IAP overexpression correlates with poor prognosis in various cancers.
- IAPs are pursued as therapeutic targets, with inhibitors under development.
Conclusions:
- IAPs have diverse roles in cell biology and are implicated in cancer.
- IAPs show promise as diagnostic markers and therapeutic targets in oncology.
- Integrating IAP findings into clinical practice remains a significant challenge.